InvestmentPitch Media Video Discusses FSD Pharma’s Submission of an Investigational New Drug or “IND” Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder
The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.
- The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.
- If these links are not enabled, please visit www.InvestmentPitch.com and enter FSD Pharma in the search box.
- With our elite team and solid cash position, we find ourselves in a strong position initiating the efficacy trials with FSD-201.
- Further details on the clinical trial will be released as soon as the applications complete their review processes, and the clinical trial commences.